Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902219-25-000191
Filing Date
2025-05-12
Accepted
2025-05-12 10:44:45
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9552
2 JOINT FILING AGREEMENT Rule13D_JointFilingAgreement.htm EX-99 3738
  Complete submission text file 0000902219-25-000191.txt   15405
Mailing Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210
Business Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 6179515000
WELLINGTON MANAGEMENT GROUP LLP (Filed by) CIK: 0000902219 (see all company filings)

EIN.: 042683227 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 0000

Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Subject) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91591 | Film No.: 25933443
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)